Quick Win by the Algorithm: Sangamo Therapeutics (NASDAQ: SGMO) Returns Up To 278.00% In 1 Year And Promises Bright Future
” This year we continue the important work of laying the foundation for Sangamo as a sustainable, fully integrated company that develops, manufacturers and commercializes novel genomic therapies on our own and, where appropriate, in collaboration with industry partners. “
-Sandy Macrae, CEO of Sangamo.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a clinical stage biopharmaceutical company that focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene
